On July 24th, GeLongHui announced that the Phase Ib clinical trial of IMM2510 and IMM27M combined therapy for advanced solid tumors has successfully completed the first patient's administration.

IMM2510, independently developed by the Group, is a bispecific molecule targeting vascular endothelial growth factor (VEGF) and programmed cell death ligand 1 (PD-L1), using the structure of monoclonal antibody-receptor recombinant protein (mAbTrap). IMM2510 can inhibit angiogenesis, shrink tumors, and make tumor cells more sensitive to immune response, while activating T cells, natural killer cells and macrophages by blocking PD-L1/PD-1 interaction and inducing Fc-mediated antibody-dependent cell cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP) activities.

IMM27M is a new generation of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody with enhanced ADCC activity. It can induce the strong immune response of regulatory T cells with immunosuppressive effects by targeting CTLA-4 overexpression，promote the clearance of regulatory T cells from the tumor microenvironment (TME), and enhance the anti-tumor response of T cells.